ABOUT 2nd_EHTF
> REGISTRATION
> AGENDA
> ATTENDEES
> INVESTORS
> PRESENTERS
> SPONSORS
> SUPPORTERS
> NETWORKING

> ABOUT LAST YEAR
We are pleased to announce the 2nd Annual European HealthTech CEO Forum (Digital & MedTech), which will take place on the 8th - 9th of March 2021 and be part of the Digital Sachs Spring Life Sciences Week, the latter will also incorporate the 14th Annual European Life Sciences CEO Forum.

Due to the pandemic, Sachs Zurich events will be hosted in a digital format for the first time. This will allow us to further support our community and past attendees. We will provide both the usual stimulating program and networking opportunities through our online video and audio meeting system.

The main programme for the 2nd Annual EHTF is spread throughout 2 days (8th-9th of March) and will include HealthTech Innovation Day, focusing on Investment & Partnership in MedTech and Digital Health, and Pandemic Response Day, focusing on new developments in tackling pandemic. The programme will feature topical keynotes and panels with industry leaders as well as over 20 corporate presentations by public, private and growth companies, plus over 20 pitches by seed companies. We anticipate 300+ delegates, including major and growth corporates, financial investors/partners, bankers and advisors.

Meetings will take place from the 8th to 12th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. ​The conference will be held in the Central European Time Zone. The digital event will consist of:
HealthTech Innovation Day (Monday, 8th of March)
  • Digital Healthcare in the New Era of COVID-19 Panel
  • Digital Pharma & Drug Discovery Panel
  • MedTech & Device BD and Investment Panel
  • Revolutionising Hospital Care: New Technologies Panel
  • Innovation in Care Technology Panel
  • Innovation & Early Stage Investment Roundtable
 
Pandemic Response Day (Tuesday, 9th of March)
  • The Global Supply Chain in the Time of COVID-19 Panel
  • Overview of Vaccine Development & Roll Out Panel
  • The Challenges of Developing a Vaccine for an Emerging Country Vaccine Manufacturer
  • Advanced Therapeutics Panel
  • Diagnostics: New Technologies Panel
  • Patient Care in the Time of the Pandemic Panel

Networking Days (10th - 12th of March)
Confirmed Keynote Speakers Include:
  • Introductory Speech by Jeffrey Cohen, Managing Director, Equity Research, Ladenburg Thalmann & Co. Inc.
  • “Blitzscaling” atoms vs bytes:  Key learnings from pandemic response by Mark Stevenson, Executive Vice President & Chief Operating Officer, Thermo Fisher Scientific
  • "Vaccine Rollout Put in Israel and Global Lessons" by Prof. Ran Balicer, MD, PhD, MPh, Chief Innovation Officer, Clalit Health Services
  • Fireside Chat with Sean Marett, Chief Business Officer & Chief Commercial Officer, BioNTech SE, moderated by Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare, Clarivate
Confirmed Speakers Include:
  • Alex Zhavoronkov, Founder & CEO, Insilico Medicine, Inc.
  • Alexandra Vallon-Eberhard, Sr. Director Global BD, Roche Diagnostics
  • Amir Jafri, Founder & CEO, Immunicom, Inc.*
  • André Heeg, Managing Director & Partner, BCG Digital Ventures
  • Andreas Neubert, Chief Scientific Officer, IDT Biologika GmbH
  • Arild Kristensen, CEO, Norwegian Smart Care Cluster (NSCC)
  • Axel Nemetz, Independent
  • Beat Merz, Managing Director, New Harbor Venture Partners, LLC
  • Christoph Pedain, Head of Point of Care Diagnostics, Siemens Healthineers AG
  • Daniel O’Mahony, Partner, Seroba Life Sciences
  • Daniel Vitt, President & CEO, Immunic Therapeutics
  • David Cole, Leader EMEA, IBM Watson Health
  • David Gordon, Head of Investments, Longliv Ventures
  • Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
  • Dominik Pförringer, Academic Director of Venture Lab Healthcare, TU Munich
  • Elena Bonfiglioli, Managing Director Health and Life Sciences, EMEA, Microsoft Corporation
  • Eyal Zimlichman, Deputy Director General, CMO and CIO, Sheba Medical Center
  • Florian Schödel, Owner, Philimmune, LLC
  • Gilead Raday, COO, RedHill Biopharma Ltd.
  • Guy Spigelman, EMEA Lead, Healthcare & Life Sciences Startups, Amazon Web Services
  • Itschak Friedman, Venture Partner, LionBird (Ventures) Ltd.
  • Jan Lichtenberg, CEO, InSphero AG
  • Jeremy Sohn, VP, Global Head of Digital Business Development & Licensing, Novartis International AG
  • Jim Harper, Co-Founder & COO, Sonde Health
  • Jonathan Goldstein, Director, Corporate Research & Ventures, Boston Scientific
  • Judith Ebel, CEO, Care for Innovation e.V.
  • Julian Preibsch, Co-Founder & Managing Partner, GründerAtelier GmbH
  • Kate Broderick, Senior Vice President, Preclinical R&D, INOVIO Pharmaceuticals, Inc.
  • Klaus Stoeckemann, Co-Founder and Managing Partner, Peppermint VenturePartners GmbH
  • Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
  • Lee Newton, Chief Operating Officer, CordenPharma
  • Lionel Carnot, Partner, Earlybird Venture Capital
  • Lior Shahory, General Partner, Peregrine Ventures
  • Lloyd Diamond, President & CEO, Pixium Vision SA
  • Luciano Ravera, CEO, Humanitas Research Hospital
  • Lorenzo Positano, Partner & Managing Director, Boston Consulting Group
  • Mark Andrews, Managing Director, PharmaVentures Ltd.
  • Martin Pfister, Principal, High-Tech Gründerfonds Management GmbH
  • Martin Rothman, Venture Partner, Sofinnova Partners
  • Martin-Immanuel Bittner, Co-Founder & CEO, Arctoris Ltd.
  • Max Herrmann, Managing Director, Stifel Financial Corp.
  • Narender Mantena, Head, Global Strategy & CEO, Specialty Generic Injectables & Synthetic Biology, Biological E Ltd.
  • Nicholas​ Jackson, Head of Programmes and Innovation Technology for Vaccine R&D, Coalition for Epidemic Preparedness Innovations (CEPI)
  • ​Oliver Hennig​, SVP Operations, BioNTech SE
  • Patrick Griss, Executive Partner, Zühlke Ventures AG
  • Patrik Sobocki, Investment Lead, Industrifonden
  • Peter Julius, CEO, Public Intelligence
  • Peter Llewellyn-Davies, CEO & CFO, APEIRON Biologics AG
  • Philippe Pouletty, Co-Founder & Managing Director, Truffle Capital
  • Prashant Yadav, Senior Fellow, Center for Global Development (CGD)
  • Raghuram Selvaraju, Chairman of the Board, Relief Therapeutics Holding AG and Managing Director, H.C. Wainwright & Co., LLC
  • Rainer Metzger, Head of Integrated Clinical Services, Medicover AB
  • Rao Movva, Novartis Distinguished Scientist & Independent Pharma & Biotech Advisor, Independent - RM
  • Regina Hodits, Managing Partner, Wellington Partners
  • Richard Marsden, CEO, Synairgen Research Ltd.
  • Samuel Levy, Founding Partner, Lauxera Capital Partners
  • Ségolène Perin, Director of Innovation, ELSAN
  • Shai Novik, Executive Chairman, Enlivex Therapeutics, Ltd.
  • Stanislas Subra, Head of CVC, MACSF (Mutuelle d'assurances du corps de santé français)
  • Stefano Cazzaniga, Partner and Director, Health Care Payers & Providers, Boston Consulting Group
  • Susanne Dröscher, Co-CEO & Founder, CARU AG
  • Tamir Meiri, Senior Manager, Venture Investments, Johnson & Johnson Innovation
  • Thijs Cohen Tervaert, Junior Partner, INKEF Capital BV
  • Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC
  • Tryggvi Thorgeirsson, Co-Founder & CEO, SidekickHealth
  • ​More TBA...
SPOTLIGHT PRESENTER:
PRESENTING COMPANIES:
PARTICIPATION OPTIONS:
Free access to view live sessions is provided to all interested and qualified participants. This will allow us to increase the size of the audience and provide a higher exposure for participating companies. Additionally, you can purchase a Video on Demand pass, which will allow you to view not only live sessions, but also recordings of all sessions, in addition to speaker and company profiles and their presentations.
 
The Online Meeting System will open on the 22nd of February for uploading profiles and sending meeting invites. Meetings will take place from the 8th to 12th of March. System will allow you to have a secure audio/video call, as well as option to present slides using screen share function. Meetings will last for 30 minutes. Basic Online Meeting System Access with 10 meeting invitations will be provided complimentary for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however organizer has the discretion to reject passes. Other participants may consider purchasing Basic, Advanced and Premium Access with an option for a live spotlight or a pre-recorded showcase presentation. The number of meeting invites defines how many requests can be sent. If meeting invite is declined, you will receive an invite credit back that can be reused. The number of invites does not restrict how many meeting invitations you can receive.
PRESENTING OPPORTUNITIES:
Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically include technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.
 
​For those interested to join the companies’ showcases, there is an option to purchase either a 10 or 20 minute presentation, which will be pre-recorded in advance and available to all registered attendees before, during and after the conference on the event’s portal. There are also a limited number of 20-min Spotlight presentations with additional branding to provide even higher exposure, which will be broadcasted live during the main programme after relevant panel discussion and available on demand afterwards. Start-up companies, which are looking for seed financing may also apply for a 5 or 10 minute showcase option. The Sachs team can assist with the pre-recording of the presentation or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.
EXHIBITING OPPORTUNITIES:
Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales, and build relationships.
 
The virtual exhibition package includes a dedicated virtual page, where we can: upload your branded company’s profile and list ways to reach you; share video or images about services you provide; have files ready for download, if you wish to share any additional information with potential clients.
SPONSORING OPPORTUNITIES:
There are a limited number of sponsorship opportunities for the forum, which includes speaking, advertising and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view latest event’s sponsors here.
To learn more about presenting, exhibition or sponsorship opportunities, please contact us at SachsTeam@SachsForum.com or by phone + 44 (0)203 463 4890.
​SILVER SPONSORS:
BRONZE SPONSOR:
​CONTRIBUTING SPONSOR:
SUPPORTERS:
PARTICIPATING PHARMAS:
​FINANCIAL, ADVISORY, INVESTORS ATTENDING:
3B Future Health Ventures Sarl (Helsinn Investment Fund)
3E Bioventures
Additio Investment Group
Advent Life Sciences
Aisling Capital LLC
Aqua Partners LLC
ARCH Venture Partners
Asabys Partners
Asklepios Advisors
ATEM Capital LLC
Atlas Advisors LLC
BCG Digital Ventures
Bci
Bergmann zur Hausen & Cie. GmbH
BERNINA BioInvest Ltd.
Bioscience Managers
Biotech Alliances International, Inc.
Biotechnology Business Institute
Bootstrap Europe
Boston Scientific
Breslin AG
BRESLIN AG & LSFA
Brothers & Partners Europe
Bryan, Garnier & Co. GmbH
BTIG, LLC
Capricorn Partners NV
Cederberg GmbH
Claris Ventures
Clavis Capital Ltd.
Crosswave Management, Inc.
Curam Capital Management LLP
DeBere Capital Partners
Digital Networks Plc. S.r.l.
Dorset Capital LLC
Draper Esprit
Earlybird Venture Capital
Eaton Square
EIT Health Investor Network
European Investment Fund
Fraser Finance LLP
Fund+
Genextra S.p.A.
Global Founders Capital GmbH
Global Investment Bridge AG
Global Neurohealth Ventures
GLSV GmbH
Good Health Capital LLC
GreenSky Capital
GrowthCube Partners LLC
Guoqian VC
H.C. Wainwright
H.C. Wainwright & Co., LLC
Health Passion Fund
High-Tech Gründerfonds Management GmbH
i&i Prague s.r.o.
ICF Consult Switzerland
Illumina Ventures
Indaco Venture Partners SGR SpA
Industrifonden
INKEF Capital BV
Inserm Transfert Initiative/Sofimac
IPF Partners
Kreos Capital
Ladenburg Thalmann & Co. Inc.
Landmark Angels, Inc./ Family Office
Lauxera Capital Partners
LBBW Venture Capital
LifeCare Partners AG
LionBird (Ventures) Ltd.
Longliv Ventures
Longwall Venture Partners LLP
LSP (Life Sciences Partners)
Lundbeckfonden Ventures
MedPro Investors LLC
Mid Atlantic Bio Angels
Momentum Biotech
Moonday Capital
New Harbor Venture Partners, LLC
Novo Holdings A/S
NSIP LLC
O2H Ventures Ltd.
Optum Ventures
Pacific Channel Limited
Panacea Venture
Panakès Partners SGR SpA
Pathena
Peppermint VenturePartners GmbH
Peregrine Ventures
Pitango Venture Capital
PMV NV
Portugal Capital Ventures - Sociedade de Capital de Risco, S.A.
Redalpine Venture Partners AG
Remiges Ventures
RYSE Asset Management
Salus Partners SA
Sanan Capital
Sandhill Angels
SBI JI Innovation Advisory Ltd.
Seroba Life Sciences
Sofinnova Partners
Stifel Financial Corp.
Tandem Ventures Srl
The Fulford Group Ltd.
The Global Emerging Markets (GEM) Group
Tribeca Companies
Truffle Capital
TruVenturo GmbH
TVM Capital Life Science Venture Capital
TVM Life Science Management GmbH
Ventac Partners
Vesalius Biocapital
VI Partners AG
Viopas Partners
Vista Capital Advisors, LLC
Viva BioInnovator
Wellington Partners
Wellington Partners Venture Capital
XOventure GmbH
Zühlke Ventures AG

​To View All - Click Here